CSBTF Stock Chart & Stats
$23.91
$0.00(0.00%)
At close: 4:00 PM EDT
$23.91
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$21.20 - $42.81
Previous CloseN/A
Volume10.00
Average Volume (3M)469.00
Market Cap
$1.11B
Enterprise Value$1.09K
Total Cash (Recent Filing)$15.66M
Total Debt (Recent Filing)$3.94M
Price to Earnings (P/E)531.9
Beta0.74
Next Earnings
Aug 13, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding39,458,786
10 Day Avg. Volume795
30 Day Avg. Volume469
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$39.88Price Target Upside66.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.38
Revenue Forecast (FY)$254.90M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained multi-year revenue expansion shows the business is scaling commercial adoption and procedure-driven demand. Continued top-line growth provides a durable runway to leverage fixed costs, support R&D and sales expansion, and reduce per-unit costs over the next 2–6 months.
Very High Gross MarginsExceptionally high gross margins indicate a structurally profitable product mix and strong pricing power versus alternatives. This margin profile supports reinvestment in commercialization and cushions operating leverage, improving long-term earnings durability.
Conservative Balance SheetLow leverage and a growing asset base provide financial flexibility to fund commercialization and absorb short-term cash swings. A conservative balance sheet lowers refinancing risk and supports strategic investments or partnerships over the medium term.
Bears Say
Weak Cash ConversionDespite accounting profits in 2025, negative operating and free cash flow signal working-capital or investment drains. Persistent negative cash conversion raises near-term funding needs and could force external financing or slow commercial programs if not reversed.
Thin Net ProfitabilityNet margins are marginal and earnings superiority is recent, leaving limited buffer against slower sales, pricing pressure, or higher SG&A. Small profit margins make results sensitive to cost or demand shocks over the next several quarters.
Commercial Concentration & Adoption RiskBusiness depends on continued surgeon uptake and favorable hospital procurement, with concentrated U.S. spine exposure. Adoption, competitive alternatives, or procurement setbacks could materially impact durable procedure volumes and revenue growth.
Kuros Biosciences News
CSBTF FAQ
What was Kuros Biosciences Ltd.’s price range in the past 12 months?
Kuros Biosciences Ltd. lowest stock price was $21.20 and its highest was $42.81 in the past 12 months.
What is Kuros Biosciences Ltd.’s market cap?
Kuros Biosciences Ltd.’s market cap is $1.11B.
When is Kuros Biosciences Ltd.’s upcoming earnings report date?
Kuros Biosciences Ltd.’s upcoming earnings report date is Aug 13, 2026 which is in 11 days.
How were Kuros Biosciences Ltd.’s earnings last quarter?
Kuros Biosciences Ltd. released its earnings results on Mar 10, 2026. The company reported $0.115 earnings per share for the quarter, beating the consensus estimate of $0 by $0.115.
Is Kuros Biosciences Ltd. overvalued?
According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued.
Does Kuros Biosciences Ltd. pay dividends?
Kuros Biosciences Ltd. does not currently pay dividends.
What is Kuros Biosciences Ltd.’s EPS estimate?
Kuros Biosciences Ltd.’s EPS estimate is 0.07.
How many shares outstanding does Kuros Biosciences Ltd. have?
Kuros Biosciences Ltd. has 39,458,786 shares outstanding.
What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?
Kuros Biosciences Ltd. reported an EPS of $0.115 in its last earnings report, beating expectations of $0. Following the earnings report the stock price went up 10.105%.
Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?
Currently, no hedge funds are holding shares in CSBTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kuros Biosciences Ltd.
Kuros Biosciences AG functions as a biopharmaceutical enterprise, dedicated to both the development and market introduction of advanced therapeutic solutions for tissue regeneration and bone repair. Its operations span across the United States, the European Union, and other global regions. The company's business activities are structured into three main segments: Medical Devices, Pharmaceuticals, and a Legacy Portfolio. Its orthobiologics product line includes MagnetOs Granules and MagnetOs Putty, available in EU and US markets for various orthopedic, spinal, and dental applications. Within its fibrin/PTH orthobiologics pipeline, KUR-111 has successfully completed a Phase 2b clinical trial for treating tibial plateau fractures. Similarly, KUR-113 has concluded its Phase 2b clinical trial for tibial shaft fractures and is currently undergoing a Phase II trial for spinal interbody fusion procedures. Additionally, Kuros offers sealant products such as Neuroseal, a synthetic tissue sealant marketed in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgeries. The company also engages in a collaborative endeavor with Checkmate Pharmaceuticals LLC for the advancement of CYT003, intended for oncology treatments. Kuros Biosciences AG is headquartered in Schlieren, Switzerland.
CSBTF Company Deck
CSBTF Earnings Call
Q4 2026
0:00 / 0:00
CSBTF Stock 12 Month Forecast
Average Price Target
$39.88
▲(66.78% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Ownership Overview
―
Insiders
0.74% Mutual Funds
― Other Institutional Investors
97.17% Public Companies and
Individual Investors